Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury.

Gene Therapy Side Effects May Be Reduced by Hansa's Enzyme Therapy

An enzyme therapy developed by Swedish biotech Hansa Biopharma could help to mitigate some of the serious side effects seen with gene therapies such as Sarepta’s gene therapy Elevidys for treatment of the rare neuromuscular genetic disorder Duchenne muscular dystrophy. Hansa has announced positive results for three patients eligible for Elevidys, who were first given the enzyme therapy imlifidase to reduce the chances of an immune reaction to th…

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy - Pharmafile

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a pre-treatment to enable gene therapy in patients with Duchenne muscular dystrophy (DMD) who are otherwise ineligible. The clinical trial includes boys aged four to nine years with high levels of pre-existing antibodies to AAVrh74, the […] The post Hansa Biopharma announces positive data for Duchenne muscular dy…

Imlifidase enables gene therapy in Duchenne patients with AAV antibodies - European Biotechnology Magazine

Initial clinical data indicate that the recombinant cysteine protease imlifidase, developed by Hansa Biopharma AB, may significantly reduce levels of anti-AAV antibodies, potentially enabling adeno-associated virus (AAV)-based gene therapies in patients previously deemed ineligible due to pre-existing immunity. The post Imlifidase enables gene therapy in Duchenne patients with AAV antibodies appeared first on European Biotechnology Magazine.